Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,074.78 +4.23 (+0.08%) Dow
38,506.33 +2.64 (+0.01%) Nasdaq
15,724.49 +27.85 (+0.18%) Bitcoin USD
64,677.59 -2,126.49 (-3.18%) CMC Crypto 200
1,401.53 -22.57 (-1.58%)
Spruce Biosciences, Inc. (SPRB)
| Previous close | 0.7012 |
| Open | 0.6900 |
| Bid | 0.6907 x 400 |
| Ask | 0.7053 x 200 |
| Day's range | 0.6894 - 0.7127 |
| 52-week range | 0.6710 - 5.9500 |
| Volume | |
| Avg. volume | 1,372,025 |
| Market cap | 28.601M |
| Beta (5Y monthly) | 2.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
- Business Wire
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., March 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
- Business Wire
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
SOUTH SAN FRANCISCO, Calif., March 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH.
